ESR1 and neoplasm: In the ER+ breast cancer cell lines, a specific antibody against IGF‐1R was not able to block downstream PI3K/MAPK signaling or tumor cell proliferation, unlike the dual IGF‐1R/InsR inhibitor linsitinib.